Unrelated donor searches in Switzerland require high-resolution HLA typing for HLA-A/B/C/DRB1/DRB3,4/DQB1 loci. We evaluated this strategy accepting donors with ⩾ 9/10 match. Of 802 unrelated donor transplants in 2000-2013, 570 were 10/10 matched, 31 were DRB3/4 mismatched, 261 were single-allele mismatched and 13 had 2 allele mismatches. Of the 261 single-allele disparities, 60 concerned HLA-A/-B, 55 HLA-C and 73 HLA-DRB1/-DQB1 loci. Transplants were reduced intensity conditioning (289, 36%), marrow (187, 23%), EBMT risk score was low in 39, intermediate I in 331, intermediate II in 333 and high in 99 patients. Five-year survival was 48 ± 4%. HLA affected survival in the multivariate model adjusted for risk score. HLA-A/-B and HLA-C mismatches had twice the mortality risks, whereas HLA-DRB1/-DQB1 mismatches were similar to matched transplants. HLA-DRB3/4 mismatches were associated with a nonsignificant increased mortality risk. HLA-DRB3/4 mismatches had higher graft-versus-host disease and transplant-related mortality risks and lower relapse rates compared with matched transplants. We show significant effects of HLA class I, but not HLA class II, mismatches. The lack of impact of DRB1 disparities may be related to the lower immunogenicity of the DRB1*11:01/11:04 and DRB1*14:01/14:54 mismatches, representing 46% of DRB1 incompatibilities. These results support a matching algorithm that prioritizes mismatches considered as more permissive.
INTRODUCTION
With the increasing number of HLA-typed volunteer donors in the many donor registries worldwide, identification of a matched unrelated donor has become reality for the majority of patients with a European genetic background and in need for a hematopoietic stem cell transplant (HSCT). 1, 2 As a consequence and owing to improved outcome, 3 the number of unrelated donor transplants has steadily increased, and since 2009 it exceeds that of HLA-identical sibling donor transplants in Europe. 4 Nevertheless, even a well-matched unrelated donor HSCT remains associated with significant acute or chronic graft-versus-host disease (GVHD) and transplant-related mortality risks, and the best unrelated donor selection remains a matter of debate. [5] [6] [7] The implementation of HLA molecular typing in the donor search process has clearly contributed to improving the selection of optimally matched donors. 1 For many groups, a HLA-A/B/C/ DRB1/DQB1-compatible (that is, 5 loci, 10 alleles) donor is considered optimal with outcomes comparable to HSCTs from a HLA identical sibling donor. 8, 9 Transplant-related mortality (TRM) is clearly linked to the level of HLA matching, but to a variable degree in different populations. 10 The impact of single-allele mismatches may also vary throughout time in the same centers.
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Data on additional matching for HLA-DPB1 have led to controversial results. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] An analysis of 45000 patients with a myeloablative HSCT within the framework of the 14th international histocompatibility workshop (IHWS) showed that DPB1 incompatibilities correlated with an increased risk of aGvHD and a decreased disease relapse rate without any significant impact on the probability of overall survival. 17 The large NMDP (National Marrow Donor Program) study was also unable to disclose an impact on survival. 18 Because of weak linkage disequilibrium, only 12% of donor-recipient pairs that matched for 10/10 alleles in Switzerland are HLA-DPB1-matched, 21 a ratio comparable to that shown in several European studies (reviewed in Bettens et al. 21 ). Matching for DRB3/4 loci that are variably expressed is usually not considered, as some studies have shown these loci not to be associated with outcome. 22, 23 Impact of such mismatches, if present, may be explained by immunogenicity, but it may also hint toward MHC haplotype differences. Separating the 2 haplotypes by microarray hybridization with HLA-B allele-specific probes 24 has shown that patient/donor haplotype mismatching, that is, with HLA alleles not segregating on the same chromosome, was associated with an increased incidence of aGvHD. Similarly, a recent study in Germany showed survival differences among 10/10 allele-matched donor recipient pairs when the donor was from the same population group, as opposed to international donors. 25 A standardized donor search algorithm by the Swiss Blood Stem Cell Transplantation Group (SBST) requests donor and recipient 5 loci, 10 allele HLA high-resolution typing, that is, HLA-A/B/C/DRB1/ DRB3,B4/DQB1 for unrelated donor searches. Donors with a ⩾ 9/10 match grade were acceptable. HLA-A/B/C/DRB1/DQB1 allele or antigen mismatches were qualified as a mismatch (without any discrimination between allele and antigen mismatches), and HLA-DRB3/4 disparities were documented but not counted.
We made use of the mandate that all unrelated donor transplants in Switzerland are facilitated by the foundation Swiss Blood Stem Cells, that all donor recipient pairs are retyped at a high-resolution level before transplant by the Swiss National Reference Laboratory for Histocompatibility (LNRH) and that all transplant centers in Switzerland are JACIE accredited and do report full data. 2 The goal of this study was to evaluate this donor search strategy.
PATIENTS AND METHODS
This was a retrospective analysis of a cohort of all 802 patients receiving unrelated donor transplants using the donor search strategy, as specified above, and transplanted since 2000.
All 802 patient/donor pairs were matched at the second field level typing (high-resolution typing, previously referred to as 4-digit typing) for the HLA-A,B,C,DRB1/B3/B4,DQB1 loci by standard methods: PCR-SSO on microbeads arrays (Luminex Technology, LabType HD, OneLambda, Ingen, ChillyMazarin, France), PCR-SSP (Genovision, Milan Analytika AG, Rheinfelden, Switzerland) and SBT (Protrans, Endotell AG, Allschwil, Switzerland). 26 Among 802 patients, of whom 63% were male, with a median age of 44 years (range of 1-71 years), 395 (49%) were treated for acute leukemia, 155 (19%) were treated for MDS/MPN, 75 (9%) were treated for chronic leukemia, 63 (8%) were treated for lymphoma, 45 (6%) were treated for myeloma and 69 (9%) were treated for non-malignant disorders. The disease stage was early in 375 (47%) patients, intermediate in 243 (30%) patients or advanced in 184 (23%) patients (Table 1) .
Thirty-nine (5%) patients had a low pretransplant risk profile, as defined by the European group for blood and marrow transplantation (EBMT) risk score (1-2 27 ), 331 (41%) patients had intermediate I, 333 (41%) patients had intermediate II and 99 (12%) patients had a high risk. [4] [5] [6] [7] In 36% of patients, a low-intensity conditioning was applied; the stem cell source was marrow in 187 (23%) patients and peripheral blood in the remaining patients. Cord blood transplants were excluded from this analysis. In all, 367 (46%) transplants were performed in the four national transplant centers in 2000-2008 and 435 (54%) transplants were performed in 2009-2013 (Table 1) .
The 802 donor recipient pairs were HLA 10/10 matched in 570 (71%), or presented with HLA-A, 37 (5%), HLA-B, 23 (3%), HLA-C, 55 (7%), HLA-DRB1, 35 (4%), HLA-DQB1, 38 (5%), HLA-DRB3/4, 31 (4%, all of whom were otherwise 10/10 matched), or with 2/10 HLA-mismatches, 13 (2%). Mismatches were considered to be present irrespective of these being bidirectional or in graft versus host or host versus graft direction. With the exception of the DRB1*14:01/14:54 mismatch, all class I and II disparities included one or several amino acid differences in the antigen recognition site. One pair differed outside the antigen recognition site, but this difference resulted in a null allele, C*04:09 N. Out of all DRB1 mismatches, 60% concerned the DRB1*11 specificity. Of the C mismatches, 17% only were detected at the high-resolution level and included alleles within the C*03, C*07 and C*12 groups. The remaining 83% were detected already by low-resolution typing. For convenience of presentation and because of similar outcomes, HLA-A and HLA-B mismatches and HLA-DRB1 and DQB1 mismatches were pooled in order to compare HLA-A/B, HLA-C, HLA-DRB1/DQB1, HLA-DRB3/4 and multiple mismatches to the matched population. To verify the justification of this pooling, Table 1 showing baseline data and Table 2 showing the multivariate analysis also provide the data separately for each locus.
To estimate acute and chronic GvHD, transplant-related mortality and relapse incidence in patients with malignant disease, the cumulative incidence function was used, with death from other causes as defining the competing risk. To calculate survival probabilities, the Kaplan-Meier estimator was used with the log-rank test for comparisons among groups. The Cox regression model was used for multivariate analysis. For the clinical pretransplant risk factors, we used the EBMT risk score including patient age, disease stage, donor type, donor-recipient sex-matching and time from diagnosis to transplant. 27 Table 1 shows the baseline patient-, disease-and transplantspecific data for the cohort of 802 patients. Engraftment was Abbreviations: CLL = chronic lymphocytic leukemia; CML = chronic myeloids leukemia; EBMT = European group for blood and marrow transplantation; HSCT = hematopoietic stem cell transplants; MDS = myelodysplastic syndrome; MPN = myeloproliferative neoplasia. a EBMT Risk Score using patient age, disease stage, donor-recipient sex-mismatching, time interval from diagnosis to transplantation.
RESULTS
High-resolution HLA matching in unrelated donor transplantsslower in patients with HLA-A or HLA-B mismatched donor; the percentage of patients with primary nonengraftment or late graft lost was 3% in the matched group and 2, 5, 10, 3 and 8% in the groups mismatched for HLA-A/B, HLA-C, HLA-DRB1/DQB1, HLA-DRB3/4 and with multiple mismatches, respectively. Overall, these numbers of events were small (possibly with the exception of HLA-DRB1/DQB1 mismatches), and no statistical tests were done. Table 3 shows overall survival at 5 years, as well as treatmentrelated mortality and relapse incidence, in patients with malignancy and the cumulative incidence of acute grade II-IV GvHD by day 100 and the incidence of any grade of chronic GvHD by 5 years for the different HLA matching groups. Adjusted 5-year survival differences are shown in Figure 1 .
Whereas single class I mismatches, including HLA-A or -B and HLA-C, were associated with poorer survival and higher TRM in univariate analysis, the class II (HLA-DRB1, HLA-DQB1) mismatches were not. Of note, HLA-DRB3/4 mismatches were associated with lower survival, higher TRM and higher incidence of acute and chronic GvHD, although the survival differences were of borderline significance only. Donor-recipient pairs with 8/10 matches, that is, 2 mismatches, did not perform poorly, but this was a selected group of 13 mainly younger patients only (70% oage 20 years). Table 2 shows the multivariate model of survival confirming these differences adjusting for disease and EBMT risk score and stratified on transplant center.
DISCUSSION
The major finding of this study on 802 unrelated donor transplants performed in Switzerland was poorer outcome in 9/10 matched donor-recipient pairs if the HLA mismatch was in any of the class I loci (A,B and C), but not in a class II locus (DRB1 or DQB1). Of note, a mismatch in the DRB3/4 loci, not usually considered a mismatch, was associated with poorer outcome, although this difference was of borderline significance only. The lack of detectable impact of class II mismatching in this cohort may be explained by lower immunogenicity of DQB1 mismatches [22] [23] [24] [25] and by the fact that DRB1 mismatches were enriched for the possibly nonimmunogenic or weakly immunogenic HLA-DRB1*11:01/11:04 28 (identified in 14 patient/donor pairs) and DRB1*14:01/14:54 disparities (in two patient/donor pairs), which altogether comprised 46% of all HLA-DRB1-mismatched donor-recipient pairs. Of the 35 DRB1 mismatches, 4 only were accompanied by a DRB3 mismatch, with 2 of these including a DRB1*14:01/14:54 mismatch previously reported as permissive. 29 Interestingly, 22% of the DQB1 incompatibilities consisted of the DQB1*03:01/03:02 mismatch that had been shown to be undetectable in mixed lymphocyte Table 2 . Abbreviations: aGvHD = acute graft versus host disease; cGvHD = chronic graft versus host disease; GVHD = graft-versus-host disease; TRM = transplant-related mortality. culture assays. 30 Altogether, the lack of a significant impact of single DRB1/DQB1 mismatches may reflect adequate selection of 'low-risk disparities' that are associated with lower immunogenicity, most likely owing to very similar peptide binding repertoire between specific HLA alleles. The multivariate model confirms the possible impact of HLA-DRB3/4 mismatching. This model was adjusted for diagnosis and EBMT risk score and stratified on transplant center, as there were significant differences among centers in outcome. The study has limited power to detect the impact of class II mismatches on outcome, which may serve as an alternative explanation for the lack of impact of class II mismatches. This contrasts, however, with the strong impact of class I mismatches in groups of comparable size. Analyzing these center differences is not part of the present work. The possible impact of HLA-DRB3/4 mismatches may be explained by chance, by a small immunogenetic impact of these differences, by concomitant DPB1 mismatches (92.6% of the 27 donors retrospectively typed were indeed DPB1 incompatible), but also by less conserved haplotypes associated with unfavourable non-HLA polymorphisms. 7, 21 A recent study by the German registry 25 showed that HLA 10/10 matched unrelated donor transplants had better results if the donor was from Germany than if the donor was from abroad, highlighting the issue that conservation of whole MHC haplotypes may have a role in outcome of unrelated donor transplantation. In this respect, we had previously reported a beneficial impact of common and frequent haplotypes on outcome, 21 an observation that was subsequently confirmed by another laboratory. 31 Although our experience of transplants with more than one mismatch is too limited to draw any conclusions, the current strategy of SBST to accept HLA 10/10 matched donors and singleallele or antigen mismatches for unrelated transplantation appears reasonable. HLA class I mismatches, whether HLA-A, HLA-B or HLA-C, are doubling mortality risks, and this has to be taken into account. Our data do not allow the conclusion that class II mismatches are without consequences because of nonrandomly accepted mismatches, but they reveal that the strategy to favor mismatches considered as nonimmunogenic has to be pursued and analyzed further. The finding of a possible impact of HLA-DRB3/4 mismatches strengthens our strategy to systematically include DRB3/4 typing in the algorithm and to favor DRB3/4-matched donors whenever a choice is possible.
